Literature DB >> 8894572

Effects of prophylactic administration of cefaclor on transient bacteremia after dental extraction.

G Hall1, A Heimdahl, C E Nord.   

Abstract

This study was undertaken to investigate the effects of prophylactic administration of cefaclor on bacteremia after dental extraction. Thirty-nine patients were randomly assigned to receive either 1 g cefaclor (19 patients) or placebo (20 patients) 1 h prior to dental extraction. Blood samples for microbiological investigation were collected before, during, and 10 min after surgery, and were processed by lysis filtration under anaerobic conditions. The incidence of bacteremia with viridans streptococci was 79% in the cefaclor group and 50% in the placebo group during extraction. No difference in the incidence or magnitude of bacteremia was observed when the two patient groups were compared.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894572     DOI: 10.1007/bf01691150

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

Review 1.  Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci.

Authors:  A L Bisno; W E Dismukes; D T Durack; E L Kaplan; A W Karchmer; D Kaye; S H Rahimtoola; M A Sande; J P Sanford; C Watanakunakorn
Journal:  JAMA       Date:  1989-03-10       Impact factor: 56.272

2.  Antibiotic prophylaxis for infective endocarditis from an international group of experts towards a European consensus. Group of Experts of the International Society for Chemotherapy.

Authors:  C Leport; D Horstkotte; D Burckhardt
Journal:  Eur Heart J       Date:  1995-04       Impact factor: 29.983

3.  Comparison of in vitro activity of cephalexin, cephradine, and cefaclor.

Authors:  N J Bill; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

4.  Elimination of bacteraemia after dental extraction: comparison of erythromycin and clindamycin for prophylaxis of infective endocarditis.

Authors:  G Hall; C E Nord; A Heimdahl
Journal:  J Antimicrob Chemother       Date:  1996-04       Impact factor: 5.790

5.  Detection and quantitation by lysis-filtration of bacteremia after different oral surgical procedures.

Authors:  A Heimdahl; G Hall; M Hedberg; H Sandberg; P O Söder; K Tunér; C E Nord
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

Review 6.  Aetiology and epidemiology of infective endocarditis in England and Wales.

Authors:  S E Young
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

7.  Antimicrobial activity in vitro of cefaclor, a new oral cephalosporin.

Authors:  B R Meyers; S Z Hirschman
Journal:  J Clin Pharmacol       Date:  1978 Feb-Mar       Impact factor: 3.126

8.  Significance of penicillin tolerance in vivo: prevention of experimental Streptococcus sanguis endocarditis.

Authors:  J Hess; J Dankert; D Durack
Journal:  J Antimicrob Chemother       Date:  1983-06       Impact factor: 5.790

9.  Cefaclor: in vitro spectrum of activity and beta-lactamase stability.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

10.  Therapeutic significance of penicillin tolerance in experimental streptococcal endocarditis.

Authors:  R O Brennan; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

View more
  3 in total

1.  Infective endocarditis: rationale for revised guidelines for antibiotic prophylaxis.

Authors:  Prabhakaran P Gopalakrishnan; Sanjay K Shukla; Tahir Tak
Journal:  Clin Med Res       Date:  2009-07-16

Review 2.  The rationale for the new infective endocarditis guidelines.

Authors:  Ann F Bolger
Journal:  Curr Cardiol Rep       Date:  2009-03       Impact factor: 2.931

Review 3.  Microbiology of odontogenic bacteremia: beyond endocarditis.

Authors:  N B Parahitiyawa; L J Jin; W K Leung; W C Yam; L P Samaranayake
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.